ASND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Ascendis Pharma A/S (ASND) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company has strong analyst support, a promising growth trajectory, and positive catalysts from its product pipeline. While there are no immediate trading signals or recent news, the long-term potential outweighs the short-term technical neutrality.
The technical indicators are neutral to slightly bearish in the short term. The MACD is below zero and negatively contracting, RSI is at 39.798, indicating no clear signal, and moving averages are converging. The stock is trading below the pivot level of 224.577, with key support at 214.945 and resistance at 234.21.
The company has three approved products powered by its TransCon platform, with Yorvipath on a strong growth trajectory and Yuviwel positioned to disrupt the achondroplasia market. Analysts have raised price targets significantly, citing FDA approvals and strong revenue growth potential.
Hedge funds are selling the stock, with a significant increase in selling activity (565.41% over the last quarter). There is no recent news or congress trading data to provide additional support.
In Q4 2025, the company reported revenue of $247.5M with no YoY growth. Net income improved to -$33.56M, and EPS increased to -0.55. Gross margin remains strong at 90.47%. While the company is not yet profitable, its financials indicate strong operational efficiency and potential for future growth.
Analysts are overwhelmingly positive on ASND, with multiple firms maintaining Buy or Outperform ratings and raising price targets. Recent price targets range from $250 to $332, reflecting confidence in the company's growth trajectory and product pipeline.
